Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death…
Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a PresentationTAIPEI, Taiwan,…
Marks third FDA designation for ATSN-201, which has also received Rare Pediatric Disease Designation and Orphan Drug DesignationDURHAM, N.C., March…
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of…
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Study Demonstrates Excess Visceral Abdominal Fat Drives CV RiskMONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the…
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough…
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for…
ST. PETERSBURG, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- This is a comprehensive examination of the groundbreaking research behind Prime…
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing…